The US government purchases more doses of monoclonal antibody treatments for Covid-19, and the Biden administration takes over distribution in order to avoid shortages of major therapeutics. The measures come as demand for monoclonal antibodies has increased as cases have increased due to the spread of the Delta variant and low vaccination rates in some regions of the country. Monoclonal antibodies are proteins of the immune system designed in the laboratory that trigger an immune response against infection. The US Department of Health and Human Services reports that as of September 10, 2.17 million doses of monoclonal antibodies have been shipped to all sites, and 938,000 doses have been used since December. Approximately 43% of the doses distributed have been used by September 3.